Cargando…

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study

BACKGROUND: Evidence on PD-1/PD-L1-directed immune checkpoint inhibitor (ICI) therapy for advanced non-small-cell lung cancer (NSCLC) is mainly based on clinical trials in first- or second-line settings. OBJECTIVE: We aimed to investigate response and prognostic factors with special regard to third-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, David, Huemer, Florian, Rinnerthaler, Gabriel, Horner, Andreas, Wass, Romana, Brehm, Elmar, Akbari, Kaveh, Granitz, Marcel, Hutarew, Georg, Kaiser, Bernhard, Greil, Richard, Lamprecht, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875512/ https://www.ncbi.nlm.nih.gov/pubmed/31654203 http://dx.doi.org/10.1007/s11523-019-00679-9

Ejemplares similares

Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
por: Lang, David, et al.
Publicado: (2021)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2020)

Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity
por: Wass, Romana, et al.
Publicado: (2022)

First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
por: Lang, David, et al.
Publicado: (2021)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
por: Hutarew, Georg
Publicado: (2016)

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics
por: Huemer, F, et al.
Publicado: (2019)

Potential influence of automated volumetry on treatment response classifications in lung cancer lesions
por: Akbari, Kaveh, et al.
Publicado: (2014)

Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
por: Huemer, Florian, et al.
Publicado: (2020)

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature
por: Heregger, R., et al.
Publicado: (2021)

Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score
por: Shao, Guangyu, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
por: Nosrati, Adi, et al.
Publicado: (2017)

Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study
por: Lang, David, et al.
Publicado: (2021)

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
por: Ebot, Ericka M., et al.
Publicado: (2022)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
por: Voutsadakis, Ioannis A
Publicado: (2020)

Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
por: Malet, Julie, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
por: Isla, Dolores, et al.
Publicado: (2023)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
por: Lin, Zhijuan, et al.
Publicado: (2016)

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
por: Catanese, Silvia, et al.
Publicado: (2020)

Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice
por: van Zeijl, Michiel C. T., et al.
Publicado: (2021)

Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases—Network-analyses and multivariate models
por: Lang, David, et al.
Publicado: (2020)

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade
por: Milberg, Oleg, et al.
Publicado: (2019)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
por: Barata, Pedro, et al.
Publicado: (2020)

Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
por: Nie, Run-Cong, et al.
Publicado: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis
por: Yang, Yilin, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Oncolytic adenovirus H101 ameliorate the efficacy of anti‐PD‐1 monotherapy in colorectal cancer
por: Huang, Lili, et al.
Publicado: (2022)

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e5go4st5c1katdq6l0qqg1kltg